⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MESO News
Mesoblast Limited American Depositary Shares
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
globenewswire.com
MESO
Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
globenewswire.com
MESO
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
prnewswire.com
FBLG
MESO
LGVN
FATE
Ryoncil® Profits Underpinning Substantial Growth Pipeline
globenewswire.com
MESO
Mesoblast Financial Results and Corporate Update Webcast
globenewswire.com
MESO
Stem Cell Therapy Market to Reach USD 45.2B by 2036 (8.4% CAGR) | U.S., Germany & Japan Lead Growth | Mesenchymal Stem Cells Hold 45% Share -- Future Market Insights
prnewswire.com
MESO
GERN
BCDA
NVS
BMY
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
globenewswire.com
MESO
Ryoncil® Net Revenues Increase for the Quarter to US$30M
globenewswire.com
MESO
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
globenewswire.com
MESO
FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
globenewswire.com
MESO